NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bone Biologics Corporation (BBLG) Stock Analysis

Bone Biologics Corporation (BBLG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BBLG

$0.57

+$0.01 (+1.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BBLG with… →

BBLG Key Statistics

As of Sep 4, 2026
Trading
Open
$0.58
Previous Close
$0.56
Day's Range
0.54–0.58
52-Week Range
0.54–2.89
Volume
15.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
$1.57M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.29
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$3.11M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.76M
1-Year Return
−80.07%
Dividend and dates
Avg Volume
339.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BBLG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.83%
2025−74.29%
2024−79.20%
2023−91.03%
2022−94.03%
2021 (partial year)−30.84%

As of September 4, 2026.

BBLG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$3.11M—
2024$0.00−$4.11M—
2023$0.00−$8.95M—
2022$0.00−$1.48M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$3.23M−$3.11M—
2024$0.00—−$4.22M−$4.11M—
2023$0.00—−$9.43M−$8.95M—
2022$0.00$0.00−$3.67M−$1.48M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BBLG Valuation vs Biotechnology Median

Median of 656 stocks
MetricBBLGBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Bone Biologics Corporation (BBLG) at $1.57M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

The most recent close on file for BBLG is $0.57, dated September 4, 2026. That is +$0.01 (+1.79%) against the previous close. Over the past 52 weeks the price has ranged from $0.54 to $2.89. The latest close sits 5.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $3.11M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −80.07%. Measured over 3 years, that is −73.97% a year compounded. Beta against the wider market is reported at 0.5. Daily returns over the trailing 4 years annualize to a volatility of 136.14%.

Growth & Income

No dividend is on file for BBLG.

Across the complete calendar years on file, 2025 returned −74.29% and 2022 returned −94.03%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −60.83% year to date.

Peer Comparison

Bone Biologics Corporation (BBLG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bone Biologics Corporation BBLG $1.57M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bone Biologics Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bone Biologics Corporation

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Visit website →